Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/17/suppl_4/iv31/436550/mdj996.pdf
Reference7 articles.
1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin’s lymphoma;Philip;N Engl J Med,1995
2. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury;Shipp;J Clin Oncol,1999
3. Rituximab and ICE as second line before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma;Kewalramani;Blood,2004
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002
5. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte;Feugier;J Clin Oncol,2005
Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma;OncoImmunology;2024-03-03
2. Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience;Journal of Clinical Apheresis;2023-11-08
3. 2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma;American Journal of Hematology;2023-08-30
4. Autologous Transplantation May Still Effectively Treat Relapsed Diffuse Large B-Cell Lymphoma in Selected Patients;Cancers;2023-06-16
5. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma;Expert Review of Anticancer Therapy;2023-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3